<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650727</url>
  </required_header>
  <id_info>
    <org_study_id>P07974</org_study_id>
    <secondary_id>2012-001437-14</secondary_id>
    <secondary_id>MK-7965-011</secondary_id>
    <nct_id>NCT01650727</nct_id>
  </id_info>
  <brief_title>A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)</brief_title>
  <official_title>A Phase 1b Trial of Dinaciclib in Combination With Rituximab in Subjects With Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib
      therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small
      lymphocytic lymphoma (SLL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing a Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Cycles 2 &amp; 3 (Days 29-84)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dinaciclib + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab will be administered in Cycles 1 and 3-13.
Dinaciclib will be administered in Cycles 2-13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinaciclib</intervention_name>
    <description>Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m^2 up to a maximum dose of 14 mg/m^2.</description>
    <arm_group_label>Dinaciclib + Rituximab</arm_group_label>
    <other_name>SCH 727965</other_name>
    <other_name>MK-7965</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).</description>
    <arm_group_label>Dinaciclib + Rituximab</arm_group_label>
    <other_name>Rituxan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have received at least one prior therapy that includes either

        fludarabine or equivalent nucleoside analogue or an alternative regimen

          -  Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic

        lymphoma (SLL)

          -  Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2

          -  Women of child-bearing potential who are sexually active, ,including both female
             subjects and the female sexual partners of male subjects, must agree to use a
             medically accepted method of contraception prior to enrollment, while receiving
             protocol-specified treatment, and for 12 months after stopping study treatment.

          -  Women of child-bearing potential who are not currently sexually active must

        agree to use a medically accepted method of contraception should they become

        sexually active while participating in the study.

          -  Life expectancy ≥12 weeks

        Exclusion Criteria:

          -  Symptomatic brain metastases or primary central nervous system malignancy

          -  Treatment with any chemotherapy or biologic therapy within 4 weeks prior to enrollment

          -  Non-hematological toxicities from prior therapy

          -  Presence of any serious or uncontrolled infection defined as infection requiring
             hospital admission and/or parenteral antibiotics

          -  Known human immunodeficiency virus (HIV) infection or a known HIV-related

        malignancy

          -  Clinically active hepatitis B or C defined as disease that requires

        therapy

          -  Women who are breast-feeding, pregnant, or intend to become pregnant

          -  Prior allogeneic bone marrow transplant (auto hematopoietic stem cell

        transplantation [HSCT] is allowed if fully recovered)

          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer or other cancer from which the subject is

        considered by his or her physician to have a 2 year survival expectation

          -  Any investigational drugs within 4 weeks prior to the start of treatment

          -  Concurrently receiving treatment in any other clinical study

          -  Previously treated with a cyclin dependent kinase (CDK) inhibitor (e.g., dinaciclib or
             flavopiridol)

          -  Active autoimmune anemia or idiopathic thrombocytopenic purpura (ITP) unless

        stable, defined as being responsive to corticosteroids or other standard therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Fabre C, Gobbi M, Ezzili C, Zoubir M, Sablin MP, Small K, Im E, Shinwari N, Zhang D, Zhou H, Le Tourneau C. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol. 2014 Nov;74(5):1057-64. doi: 10.1007/s00280-014-2583-9. Epub 2014 Sep 13.</citation>
    <PMID>25217392</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

